Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Patel et al. Zinc for COVID-19 RCT LATE TREATMENT Is late treatment with zinc beneficial for COVID-19? Double-blind RCT 33 patients in Australia Trial underpowered to detect differences Patel et al., J. Medical Virology, doi:10.1002/jmv.26895 Favors zinc Favors control
A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients
Patel et al., Journal of Medical Virology, doi:10.1002/jmv.26895
Patel et al., A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in.., Journal of Medical Virology, doi:10.1002/jmv.26895
Feb 2021   Source   PDF  
  All Studies   Meta
Small early terminated RCT with 33 hospitalized patients in Australia, 15 treated with zinc, showing no significant difference in clinical outcomes. Treatment increased zinc levels above the deficiency cutoff. Intravenous zinc 0.5mg/kg/day (elemental zinc concentration 0.24mg/kg/day) for up to 7 days. ACTRN12620000454976.
Although the 20% lower mortality is not statistically significant, it is consistent with the significant 29% lower mortality [9‑44%] from meta analysis of the 19 mortality results to date.
risk of death, 20.0% lower, RR 0.80, p = 1.00, treatment 2 of 15 (13.3%), control 3 of 18 (16.7%), NNT 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 25 Feb 2021, Double Blind Randomized Controlled Trial, Australia, peer-reviewed, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: Received: 6 December 2020 | Revised: 18 January 2021 | Accepted: 20 January 2021 DOI: 10.1002/jmv.26895 SHORT COMMUNICATION A pilot double‐blind safety and feasibility randomized controlled trial of high‐dose intravenous zinc in hospitalized COVID‐19 patients Oneel Patel1 | Vidyasagar Chinni1,2 | John El‐Khoury1,2 | Marlon Perera1,2 | Ary S. Neto3,4 | Christine McDonald5 | 1,6 | Damien Bolton Daryl Jones 1,2 Joseph Ischia 1 Department of Surgery, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia 1,2 | 4,6 Rinaldo Bellomo Emily See6 | Jason Trubiano | 7 | Abstract Zinc inhibits replication of the SARS‐CoV virus. We aimed to evaluate the 2 Department of Urology, Austin Health, Heidelberg, Victoria, Australia safety, feasibility, and biological effect of administering high‐dose intravenous 3 zinc (HDIVZn) to patients with COVID‐19. We performed a Phase IIa double‐ Australian and New Zealand Intensive Care‐Research Centre, Monash University, Melbourne, Victoria, Australia 4 Centre for Integrated Critical Care, The University of Melbourne, Parkville, Victoria, Australia 5 Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia 6 Department of Intensive Care, Austin Hospital, Heidelberg, Victoria, Australia blind, randomized controlled trial to compare HDIVZn to placebo in hospitalized patients with COVID‐19. We administered trial treatment per day for a maximum of 7 days until either death or hospital discharge. We measured zinc concentration at baseline and during treatment and observed patients for any significant side effects. For eligible patients, we randomized and administered treatment to 33 adult participants to either HDIVZn (n = 15) or placebo (n = 18). We observed no serious adverse events throughout the study for a total of 94 HDIVZn administrations. However, three participants in the HDIVZn group 7 Department of Infectious Disease, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia Correspondence Joseph Ischia, Department of Surgery, The University of Melbourne, Austin Health, Heidelberg, VIC, Level 8, Lance Townsend Building, Australia. Email: reported infusion site irritation. Mean serum zinc on Day 1 in the placebo, and the HDIVZn group was 6.9 ± 1.1 and 7.7 ± 1.6 µmol/l, respectively, consistent with zinc deficiency. HDIVZn, but not placebo, increased serum zinc levels above the deficiency cutoff of 10.7 µmol/l (p < .001) on Day 6. Our study did not reach its target enrollment because stringent public health measures markedly reduced patient hospitalizations. Hospitalized COVID‐19 patients demonstrated zinc deficiency. This can be corrected with HDIVZn. Such treatment appears safe, feasible, and only associated with minimal peripheral infusion site irritation. This pilot study justifies further investigation of this treatment in COVID‐19 patients. KEYWORDS COVID‐19, randomized controlled trial, trial protocol, zinc Abbreviations: HDIVZn, high dose intravenous zinc; HFNC, high‐flow nasal cannula; NIV, noninvasive ventilation. J Med Virol. 2021;93:3261–3267. © 2021 Wiley Periodicals LLC | 3261 3262 1 | PATEL | INTRODUCTION 2 | Cheap, safe, and easily administered interventions to improve ET AL. ME THO D S 2.1 | Human ethics outcomes associated with COVID‐19 infection remain an important goal. Zinc and Zn‐salts inhibit viral infections..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop